SMC6

Across TCGA pan-cancer cohorts, SMC6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SMC6 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SMC6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SMC6 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where SMC6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.968	0.806	.010	20	view →
LSCC	OS	Tertile	II,III,IV	0.939	0.591	.008	15	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
GBM	OS	Quartile	All	0.568	0.308	.014	2	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SMC6–CCRCC (OS)

Open the CCRCC breakdown →